Kornimate/medical-research-clean huggingface dataset:
breathing intervention for cardiac anxiety

Conditions: Atrial Fibrillation; Implantable Cardioverter Defibrillator

Summary: this study examines the impact of a breathing training intervention on cardiorespiratory sensations and anxiety in adults with cardiac arrhythmias.

patients with cardiac arrhythmias develop increased rates of anxiety and depression. atrial arrhythmias, such as paroxysmal atrial fibrillation (af), and ventricular arrhythmias, such as those with implantable cardioverter defibrillators (icd) are particularly at risk. while icds can be life saving, many patients (including those without prior psychiatric illness) develop elevated rates of anxiety and depression, particularly after receiving discharges (shocks) from the device. treatments involving modulation of the breath have been shown to improve both psychological and cardiac outcomes in patients with af. since breathing modulation alters sympathetic balance, this may be a mechanism of the therapeutic effect. this study examines the impact of a breathing training intervention on cardiorespiratory sensations and anxiety in adults with atrial and ventricular cardiac arrhythmias.

Eligibility criteria:
inclusion criteria: * age 18 to 80 * bmi 17 to 35 * proficient in english language * paroxysmal atrial fibrillation or ventricular fibrillation or frequent premature atrial/ventricular contractions exclusion criteria: * no telephone access * active suicidal ideation with intent or plan * active drug or alcohol dependence, or active binge drinking within the last month * cardiovascular instability, as evidenced any of the following: 1. new york heart association (nhya) heart failure class iv (i.e., unable to carry on any physical activity without discomfort, symptoms of heart failure at rest, increased discomfort with any physical activity is undertaken) 2. american college of cardiology/american heart association congestive heart failure stage d (i.e., heart failure symptoms at rest, receiving end of life care). 3. unstable angina or exercise induced angina 4. persistent atrial fibrillation * pacemakers or combined pacemaker/icds will be excluded * presence of unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, or metabolic disease; or any other condition that, in the opinion of the investigator, would make participation not be in the best interest (e.g., compromise the well-being) of the subject or that could prevent, limit, or confound the protocol-specified assessments.
a problem solving intervention involving employees at risk of sick leave due to common mental disorders

Conditions: Mental Disorders

Summary: the overall aim of this randomized controlled trial is to evaluate the effectiveness of a problem-solving intervention for the prevention of sick leave among employees with early signs of cmds. the intervention is delivered by first-line managers and a 30% reduction in sick leave days is expected in the experimental condition compared to treatment-as-usual, during the 12- months follow-up.

the overall aim of this randomized controlled trial is to evaluate the effectiveness of a problem-solving intervention for the prevention of sick leave among employees with early signs of cmds. the intervention is delivered by first-line managers and a 30% reduction in sick leave days is expected in the experimental condition compared to treatment-as-usual, during the 12- months follow-up. in an alongside process evaluation on the intervention's core activities, i.e. identification of early signs of cmds, training of first-line managers in problem-solving and communication, we will: * evaluate whether and to what extent it was possible for the first-line managers to adhere to the intervention's protocol, * investigate the association between the intervention's core activities and number of sick leave days, * identify the facilitators and barriers to the intervention among first-line managers and employees and, * explore the first-line manager's organizational resources supporting their general managerial work. the study will be conducted in private sector companies, among first-line managers and blue-collar workers. the outcomes will be evaluated on both cluster- and individual participant level.

Eligibility criteria:
inclusion criteria: * scoring with a cut-off ≥3 points on the ghq-12, or a positive answer on the question on risk of sa, namely employee believes that he/she will receive a sickness certification due to stress, anxiety, or depression the following 12 months. * negative answer on the question on bullying, namely employee has not been exposed to bullying by his or her first line manager. * understand written and spoken swedish. exclusion criteria: * ongoing sick leave (full- or part-time), leave of absence, pregnancy. * sick leave ≥14 calendar days during the last 3 months due to cmd. * at the time for inclusion planned long-term absence during the coming year (for example parental leave, new job, retirement).
analysis of a tapered porous coated stem and a cementless hemispherical acetabular component

Conditions: Osteoarthritis, Hip

Summary: this prospective study will evaluate the hip function and quality of life of patients operated for total hip arthroplasty with masterloc femoral stem and mpact acetabular cup. the results of this study will establish the performance of masterloc femoral component (medacta international sa) and mpact acetabular component (medacta international sa), and provide a general estimate of survivorship, clinical effectiveness and complications.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis of the hip necessitating primary hip replacement, * suitability for straight cementless stem, * adult male and female under 75 years old, * ability to give informed consent , * patients who understand the conditions of the study and are willing to participate for the length of the prescribed follow-up. exclusion criteria: * off-label use of the medacta masterloc femoral component and mpact acetabular component * post-traumatic deformity in the affected hip, * patient suffering from inflammatory arthritis including rheumatoid arthritis, * patient suffering by congenital or developmental deformity, * severe osteoporosis, * history of surgery in the affected hip, * perioperative fracture, * personality disorders (dementia, alcohol or drug abuse etc) suspected of making completion of the trial uncertain, * patients with a history of active infection * pregnant women or those seeking to become pregnant
evaluation of the practice of three morning sputa on separate days for diagnosis of mtb

Conditions: Pulmonary TB

Summary: obtain sputum smears within one day to rule out tb


Eligibility criteria:
inclusion criteria: * all subjects admitted to bellevue hospital for evaluation of possible tb exclusion criteria: * unable to produce spontaneous or induced sputum
effect of individualized patient education including drinking advice using an app

Conditions: Colorectal Cancer

Summary: study evaluating the effect of a personalized smart phone application in addition to standard care on bowel preparation scores, compared to standard care alone.

picoprep is a low-volume bowel preparation used to optimize visualization of the colonic mucosa during colonoscopy. patients referred for a colonoscopy will be scheduled for an intake. during this intake patients receive education about picoprep and will be asked about their health condition (medical history, medication use). standard a face-to-face education is given by an intake nurse or doctor. the producers of picoprep, ferring bv designed an app including a drinking schedule adapted to the timing of the coloscopy, aiming a lag time between intake of the last picoprep dose and the scopy of 2-4 hours. we hypothesize that the boston bowel preparation scale and patient satisfaction will be higher in patients receiving standard education plus using the bowel preparation app versus patients receiving single standard education.

Eligibility criteria:
inclusion criteria: * patients refered to our clinic for colonoscopy by general practitioner, colorectal cancer screening programme or outpatient clinic * use of regular sodium picosulfate bowel preparation scheme * possession of an android or ios smart phone exclusion criteria: * emergency colonoscopy * hospitalized patients

Keywords: bowel preparation colonoscopy smart phone application patient satisfaction
cardiac changes associated with acute cerebro-vascular stroke

Conditions: Cerebrovascular Accident

Summary: cardiovascular disease is regarded as main predisposing risk factor for cerebrovascular stroke. cardiac dysfunction can both worsen the pre existing cerebral damage and cause new brain injury diseases of the heart and the brain are closely entangled. vascular diseases of both organs share the same risk factors.


Eligibility criteria:
inclusion criteria: 1. above 18 years 2. patients presented with cerebrovascular stroke 3-patients diagnosed as cardiac patients and have cerebrovascular stroke exclusion criteria: 1-less than 18 years
a usability study of itear100 for combined eyelid microblepharoexfoliation and neurostimulation

Conditions: MicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye Syndrome

Summary: the purpose of this study is to evaluate the usability of the itear100 generation 2 device in combination with its newly developed ilids100 disposable cover.

this usability study is meant to validate treatment using the ilids100 in patients who already use the nulids device and itear100. the patients will simply substitute the ilids100 cover in combination with the itear100 for the nulids product and otherwise maintain their same treatment regimen. the planned number of subjects was chosen to provide clinically relevant usability data

Eligibility criteria:
inclusion criteria: must use itear and nulids at time of enrollment exclusion criteria: 1. have any condition, which in the judgment of the pi would prevent a potential subject from safely completing the study or tolerating device use, such as mental illness, dementia, severe agitation, etc. and including inability to comply with the treatment regimen.
correlation between state-trait-anxiety-inventory and heart rate variability

Conditions: Preoperative Vegetative Stress

Summary: the purpose of the study is to investigate whether there is a correlation between the vegetative stress evaluated by the state-trait-anxiety-inventory (stai-test) and the measurement of heart rate variability (hrv). a subgroup analysis will also be performed to determine whether premedication contributes to a lower stai score and/or heart rate variability. the primary outcome will be the parameter of frequency-based analysis low frequency (lf) and high frequency (hf), and the stai score. secondary outcomes are the parameters low frequency/high frequency-ratio (lf/hf-ratio), standard deviation of normal-to-normal (nn) intervals (sdnn), root mean square of successive differences" (rmssd) and mean heart rate, age, gender, if they are smokers and if they work in shifts.


Eligibility criteria:
inclusion criteria: * subjects between 18 and 65 years * elective surgery with a low risk of bleeding * american society of anesthesiologists (asa) classification 1-2 * metabolic equivalent of task (met) \> 4 exclusion criteria: * pre-existing cardiac conditions such as heart failure, arterial hypertension, * diabetes * any central nervous system diseases * cardiac pacemaker * renal and hepatic insufficiency * regional or peridural anesthesia * pregnancy, lactation * drugs that directly influence the autonomic nervous system
loc387715/htra1 variants in polypoidal choroidal vasculopathy in a korean population

Conditions: Age-Related Macular Degeneration

Summary: this study is to investigate whether variants in the loc387715 locus and the htra serine peptidase 1 (htra1) gene within the 10q26 locus are associated with polypoidal choroidal vasculopathy and whether they are associated with clinical patterns including angiographic phenotype in a korean population.

this is a cross-sectional case-control study. one hundred korean patients with polypoidal choroidal vasculopathy and 100 control subjects were genotyped for the loc387715 (rs10490924) and the htra1 gene polymorphism (rs11200638)

Eligibility criteria:
polypoidal choroidal vasculopathy group inclusion criteria: * patients older than 60 years of age at onset * polyp-like terminal aneurysmal dilations with or without branching vascular networks in indocyanine green angiography and subretinal reddish-orange protrusions corresponding to polyp-like lesions exclusion criteria: * eyes with pathologic myopia, angioid streaks, central serous chorioretinopathy, and other retinal or choroidal diseases control group inclusion criteria: * individuals without retinal diseases and without any signs of polypoidal choroidal vasculopathy or age-related macular degeneration on the bases of comprehensive ophthalmic examination results
improve oxygenation and capnographic detection during sedative egd

Conditions: Upper Airway Obstruction; Apnea, Obstructive

Summary: the purpose of this study is to compare the effect of mandibular advancement bite block and high flow nasal cannula to standard bite block for oxygenation, capnographic measurement, prevention of hypoxemia, intervention events and adverse effects during endoscopic examinations.

during endoscopic examinations, especially during those performed via oral insertion of endoscopes, an oral bite is used to protect the examination instruments and patients. during sedated endoscopic examinations, the patients are under influence of anesthetics. upper airway obstruction often occurred due to respiratory depression and airway collapse resulting in desaturation. airway management with high percentage oxygen, jaw thrust, or insertion of nasal airways by trained anesthetic personnel is required during upper airway obstruction emergencies. nasal airway is invasive and causes nasal bleeding, sinusitis and other problems. jaw thrust and bag-mask ventilation requires training and is a burden to anesthetic personnel to perform. oxygenation and capnography are important ventilatory monitors during sedative procedures. these are often influenced by open mouth breathing during upper gastrointestinal endoscopic examinations making oxygenation and capnographic measurements unreliable. in this study, we group the patients into a group using standard of care, b group using mandibular advancement oral bite and c group using high-flow nasal cannulas. after anesthetic induction, gastric endoscopy will be performed. oxygenation, end-tidal carbon dioxide, and degree of upper airway obstruction will be evaluated and recorded. differences between the groups will be evaluated.

Eligibility criteria:
inclusion criteria: * male and female patients aged 20 to 80 years with asa physical status i to ii undergoing routine outpatient upper gastrointestinal endoscopy exclusion criteria: * baseline oxygen saturation \< 90% * known upper airway obstruction, difficult intubation history * unstable or lost of upper and lower incisors * known past oral or neck surgeries * anticipate exam time \> 30 mins

Keywords: intravenous sedation esophagogastroduodenalscopy upper airway mandibular advancement device high flow nasal cannula
a study to assess the safety, tolerability, and efficacy of ndi-219216 in patients with advanced solid tumors.

Conditions: Advanced Solid Tumors Cancer; MSI-H Cancer

Summary: the goal of this clinical trial is to learn if ndi-219216 is safe for patients, and if ndi-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. the main questions it aims to answer are: is ndi-219216 safe and what kinds of side effects might it cause? what kind of effects does ndi-219216 have on the body? does ndi-219216 have any impact on tumor size? participants will: take ndi-219216 every day by mouth. visit the clinic 6 times during cycle 1, 2 times during cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. after the end of study, a follow up will occur but can be done on the phone. keep a diary of their tablet consumption and symptoms experienced.

study 9216-101 is a first-in-human (fih), phase 1/2, open-label, dose escalation, dose optimization, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (pk), pharmacodynamics, and preliminary antitumor activity of ndi-219216 in patients with advanced solid tumors.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * have unresectable and/or metastatic solid tumors (with or without msi-h/dmmr) refractory to or intolerant to previous soc therapy or for which no soc therapy exists * presence of measurable disease according to recist version 1.1 except for part a (dose escalation) * adequate bone marrow / hematologic, end-organ, and cardiovascular function * resolution of all acute (or toxic) adverse effects of prior therapies, radiation therapy, or surgical procedures to grade ≤ 1 (except fatigue, alopecia, and peripheral neuropathy). exclusion criteria: * clinically significant cardiovascular disease. * patients with known wrn syndrome. * pregnancy, breastfeeding, or intention of becoming pregnant during the study.

Keywords: advanced solid tumors microsatellite instability deficient mismatch repair werner syndrome helicase
pembro with radiation with or without olaparib

Conditions: Prostate Cancer

Summary: this trial will evaluate whether the immune-sensitizing effects of immunotherapy (pembrolizumab) and radiation with or without a parp-inhibitor (olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.

immunotherapy and parp-inhibitor are known to have radio-sensitizing effects when combined with radiation therapy. in addition, the combination with parp-inhibitor and radiation can increase neoantigen expression, cytotoxic lymphocyte infiltration within the tumor microenvironment and increased immune stimulating cytokine concentration. thus, there is a potential synergy of combining immunotherapy and parp-inhibitor. this is a phase 2 randomized 1:1 study. subjects will be randomized to one arm (pembro + parpi + standard of care therapy which is definitive radiation therapy combined with hormonal therapy) vs. another arm (pembro + standard of care therapy). all subjects will receive adjuvant immunotherapy for one year once they are done with definitive radiation treatment.

Eligibility criteria:
inclusion criteria: * male participants with histologically confirmed adenocarcinoma of the prostate * high-risk / very high-risk status per nccn guidelines * ecog performance status 0 to 1 * regional lymph nodes are allowed. * agree to use contraception during the treatment period and for at least 120 days after the last dose of study intervention and refrain from donating sperm during this period. * ability to understand and the willingness to sign a written informed consent document. * adequate organ and marrow function * prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation is ≤90 days prior to the date of registration * prior 5-alpha reductase inhibitor (for example, finasteride) for prostatic hypertrophy is allowed if discontinued at least 60 days prior to registration. * known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the new york heart association functional classification. exclusion criteria: * psa \> 150ng/ml * prior hormonal therapy with lhrh agonists (e.g., lupron) and lhrh antagonists (e.g., degarelix)for prostate cancer continuously for more than 90-days prior to study enrollment. * prior radiation to the prostate. previous pelvic rt or major surgery (colorectal anastomosis, total cystectomy, radical prostatectomy, turp, etc.). history of ulcerative proctitis. * concurrent active, additional malignancy in the last 2 years. * prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization. * patients with m1 disease

Keywords: immunotherapy parp radiation androgen deprivation therapy adt pd-1
identifying biomarkers in alzheimer's disease

Conditions: Neuro-Degenerative Disease; Alzheimer Disease

Summary: alzheimer's disease is a severe neurodegenerative disorder of the brain that is characterized by progressive loss of memory and cognitive decline. with the ageing population, ad is a major public health problem affecting nearly 35 million people worldwide with numbers projected to rise to 115.4 million by 2050. ad is the only cause of death among the top ten causes that has no prevention or cure . it is believed that novel treatment of ad needs to start early or even at the prodromal stage in order to be effective. therefore, there is an urgent need to find accurate methods of early detection before patients with ad develop clinical dementia. this study aims to identify biomarkers for ad in local chinese population. this study hypothesizes blood-based proteomics, retinal imaging, asl-mrp and tau pet can improve the accuracy and staging of ad.

this is a cohort study. it involves baseline and 6 yearly follow ups. at baseline, all participants will go through a list of cognitive assessments, blood taking, brain mri scan, brain pet scan and retinal imaging. at the first five yearly follow ups, cognitive assessment will be performed. for the sixth yearly follow up, automatic retinal image will be performed in addition to cognitive assessment.

Eligibility criteria:
inclusion criteria: * chinese ethnicity * \[for dementia group, clinical diagnosis of "probable alzheimer's disease" according to recommendation from the national institute on aging-alzheimer's association workgroups (nia-aa) exclusion criteria: * clinical diagnosis of non-ad dementia * contraindication for mri or pet

Keywords: alzheimer disease
a phase iia study of mk0457 in patients with cancer of the lung (0457-006)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.


Eligibility criteria:
inclusion criteria: * patients who are at least 18 years of age with cancer of the lung and who have had either no previous treatment or 1 previous treatment for advanced cancer of the lung. certain other treatments may also be allowed (prior cytotoxic chemotherapy in the adjuvant setting) exclusion criteria: * patients who have had treatment with any investigational therapy within the past 30 days are not eligible. * patients who have had a disease or medical condition that is not controlled will not be eligible. * patients who are pregnant or breastfeeding are not eligible.

Keywords: advanced non-small cell lung cancer nsclc